Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials.

Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. Lancet Oncol. 2015 Jul; 16(7):848-58.

View in: PubMed

subject areas

Administration, Oral
Adult
Antineoplastic Agents, Hormonal
Breast Neoplasms
Chemotherapy, Adjuvant
Disease-Free Survival
Dose-Response Relationship, Drug
Drug Administration Schedule
Early Detection of Cancer
Female
Follow-Up Studies
Humans
Middle Aged
Neoplasm Invasiveness
Neoplasm Staging
Ovary
Premenopause
Quality of Life
Risk Assessment
Self Report
Survival Analysis
Tamoxifen
Treatment Outcome

authors with profiles

Gini Fleming